Characteristics according to AIC cluster: DLBCL diagnosed within HMRN, September 2004 to August 2012
| Characteristic . | Genetic subtype, n (%) . | |||||
|---|---|---|---|---|---|---|
| NEC . | SOCS1/SGK1 . | TET2/SGK1 . | MYD88 . | BCL2 . | NOTCH2 . | |
| All subtypes combined | 248 (100) | 111 (100) | 98 (100) | 152 (100) | 176 (100) | 143 (100) |
| DLBCL NOS | 211 (85.1) | 98 (88.3) | 91 (92.9) | 130 (85.5) | 173 (98.3) | 136 (95.1) |
| PCNSL | 9 (3.6) | 0 (0.0) | 1 (1.0) | 22 (14.5) | 0 (0.0) | 1 (0.7) |
| Primary mediastinal | 2 (0.8) | 12 (10.8) | 0 (0.0) | 0 (0.0) | 3 (1.7) | 3 (2.1) |
| T-cell/histiocyte-rich | 16 (6.5) | 1 (0.9) | 2 (2.0) | 0 (0.0) | 0 (0.0) | 2 (1.4) |
| Plasmablastic | 9 (3.6) | 0 (0.0) | 4 (4.1) | 0 (0.0) | 0 (0.0) | 1 (0.7) |
| Intravascular | 1 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| De novo/transformed | ||||||
| De novo | 237 (95.6) | 110 (99.1) | 93 (94.9) | 150 (98.7) | 155 (88.1) | 135 (94.4) |
| Transformed* | 11 (4.4) | 1 (0.9) | 5 (5.1) | 2 (1.3) | 21 (11.9) | 8 (5.6) |
| DLBCL with concurrent FL† | 9 (3.6) | 10 (9.0) | 2 (2.0) | 2 (1.3) | 47 (26.7) | 15 (10.5) |
| Testicular involvement‡ | 4 (2.8) | 1 (1.8) | 0 (0.0) | 21 (26.9) | 0 (0.0) | 2 (3.1) |
| Breast involvement‡ | 2 (2.5) | 0 (0.0) | 1 (2.0) | 9 (12.9) | 1 (1.1) | 0 (0.0) |
| Cell of origin§ | ||||||
| Classic | ||||||
| GCB | 43 (30.3) | 56 (86.2) | 33 (66.0) | 5 (8.2) | 92 (82.1) | 36 (37.9) |
| ABC | 38 (26.8) | 4 (6.2) | 5 (10.0) | 50 (82.0) | 3 (2.7) | 42 (44.2) |
| Unclassified | 61 (43.0) | 5 (7.7) | 12 (24.0) | 6 (9.8) | 17 (15.2) | 17 (17.9) |
| Refined | ||||||
| GCB | 36 (25.4) | 51 (78.5) | 31 (62.0) | 5 (8.2) | 78 (69.6) | 33 (34.7) |
| ABC | 38 (26.8) | 4 (6.2) | 5 (10.0) | 49 (80.3) | 3 (2.7) | 41 (43.2) |
| MHG | 7 (4.9) | 5 (7.7) | 2 (4.0) | 1 (1.6) | 15 (13.4) | 4 (4.2) |
| Unclassified | 61 (43.0) | 5 (7.7) | 12 (24.0) | 6 (9.8) | 16 (14.3) | 17 (17.9) |
| Age at diagnosis (range), y | 67.0 (12.1-95.2) | 66.8 (13.5-97.8) | 72.7 (22.8-92.0) | 70.2 (35.1-97.4) | 66.4 (24.1-88.8) | 70.2 (8.5-95.8) |
| R-CHOP treated | 172 (69.4) | 85 (76.6) | 70 (71.4) | 80 (52.6) | 141 (80.1) | 100 (69.9) |
| 5-y OS (%, 95% CI) | 53.6 (47.7-60.2) | 64.9 (56.6-74.4) | 60.1 (51.1-70.6) | 42.1 (34.9-50.7) | 62.5 (55.7-70.1) | 48.1 (40.5-57.0) |
| R-CHOP treated (%, 95% CI) | 65.6 (58.9-73.1) | 80.0 (71.9-89.0) | 69.8 (59.8-81.5) | 63.8 (54.0-75.2) | 69.5 (62.3-77.5) | 58.8 (49.8-69.3) |
| Characteristic . | Genetic subtype, n (%) . | |||||
|---|---|---|---|---|---|---|
| NEC . | SOCS1/SGK1 . | TET2/SGK1 . | MYD88 . | BCL2 . | NOTCH2 . | |
| All subtypes combined | 248 (100) | 111 (100) | 98 (100) | 152 (100) | 176 (100) | 143 (100) |
| DLBCL NOS | 211 (85.1) | 98 (88.3) | 91 (92.9) | 130 (85.5) | 173 (98.3) | 136 (95.1) |
| PCNSL | 9 (3.6) | 0 (0.0) | 1 (1.0) | 22 (14.5) | 0 (0.0) | 1 (0.7) |
| Primary mediastinal | 2 (0.8) | 12 (10.8) | 0 (0.0) | 0 (0.0) | 3 (1.7) | 3 (2.1) |
| T-cell/histiocyte-rich | 16 (6.5) | 1 (0.9) | 2 (2.0) | 0 (0.0) | 0 (0.0) | 2 (1.4) |
| Plasmablastic | 9 (3.6) | 0 (0.0) | 4 (4.1) | 0 (0.0) | 0 (0.0) | 1 (0.7) |
| Intravascular | 1 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| De novo/transformed | ||||||
| De novo | 237 (95.6) | 110 (99.1) | 93 (94.9) | 150 (98.7) | 155 (88.1) | 135 (94.4) |
| Transformed* | 11 (4.4) | 1 (0.9) | 5 (5.1) | 2 (1.3) | 21 (11.9) | 8 (5.6) |
| DLBCL with concurrent FL† | 9 (3.6) | 10 (9.0) | 2 (2.0) | 2 (1.3) | 47 (26.7) | 15 (10.5) |
| Testicular involvement‡ | 4 (2.8) | 1 (1.8) | 0 (0.0) | 21 (26.9) | 0 (0.0) | 2 (3.1) |
| Breast involvement‡ | 2 (2.5) | 0 (0.0) | 1 (2.0) | 9 (12.9) | 1 (1.1) | 0 (0.0) |
| Cell of origin§ | ||||||
| Classic | ||||||
| GCB | 43 (30.3) | 56 (86.2) | 33 (66.0) | 5 (8.2) | 92 (82.1) | 36 (37.9) |
| ABC | 38 (26.8) | 4 (6.2) | 5 (10.0) | 50 (82.0) | 3 (2.7) | 42 (44.2) |
| Unclassified | 61 (43.0) | 5 (7.7) | 12 (24.0) | 6 (9.8) | 17 (15.2) | 17 (17.9) |
| Refined | ||||||
| GCB | 36 (25.4) | 51 (78.5) | 31 (62.0) | 5 (8.2) | 78 (69.6) | 33 (34.7) |
| ABC | 38 (26.8) | 4 (6.2) | 5 (10.0) | 49 (80.3) | 3 (2.7) | 41 (43.2) |
| MHG | 7 (4.9) | 5 (7.7) | 2 (4.0) | 1 (1.6) | 15 (13.4) | 4 (4.2) |
| Unclassified | 61 (43.0) | 5 (7.7) | 12 (24.0) | 6 (9.8) | 16 (14.3) | 17 (17.9) |
| Age at diagnosis (range), y | 67.0 (12.1-95.2) | 66.8 (13.5-97.8) | 72.7 (22.8-92.0) | 70.2 (35.1-97.4) | 66.4 (24.1-88.8) | 70.2 (8.5-95.8) |
| R-CHOP treated | 172 (69.4) | 85 (76.6) | 70 (71.4) | 80 (52.6) | 141 (80.1) | 100 (69.9) |
| 5-y OS (%, 95% CI) | 53.6 (47.7-60.2) | 64.9 (56.6-74.4) | 60.1 (51.1-70.6) | 42.1 (34.9-50.7) | 62.5 (55.7-70.1) | 48.1 (40.5-57.0) |
| R-CHOP treated (%, 95% CI) | 65.6 (58.9-73.1) | 80.0 (71.9-89.0) | 69.8 (59.8-81.5) | 63.8 (54.0-75.2) | 69.5 (62.3-77.5) | 58.8 (49.8-69.3) |
Data are presented as n (%) unless otherwise indicated. AIC, Akaike information criterion; CI, confidence interval; FL, follicular lymphoma; OS, overall survival.
Prior diagnosis: 22 FLs, 14 marginal zone lymphomas, 7 chronic lymphocytic leukemias, 2 hairy cell leukemias, and 3 Hodgkin lymphomas.
Includes FL discovered at time of DLBCL diagnosis, excluding those with prior FL diagnosis.
Sex-specific proportions.
Percentage of those with material available.